"Tegaserod"

Tegaserod: What's Old Is New Again. Irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) are common gastrointestinal disorders imposing considerable impact on the quality of life and well-being of affected individuals. A paucity of evidence-based treatment options exist for CIC and IBS-C sufferers. Tegaserod, a 5-HT agonist, has a substantial body of preclinical and clinical study evidence to support its beneficial role in modulating sensorimotor function of the luminal gastrointestinal tract. Tegaserod was first approved for use by the U.S. Food and Drug Administration for the management of IBS-C and CIC in 2002 and 2004, respectively. Tegaserod enjoyed a successful uptake in the management of these disorders during its first several years

Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data. Tegaserod is a 5-HT receptor agonist approved for irritable bowel syndrome with constipation in women <65 years of age without a history of cardiovascular ischemic events. Safety data are presented from 2 external adjudications from the 2018 Gastrointestinal Drugs Advisory Committee meeting supporting tegaserod's reintroduction after its voluntary 2007 withdrawal. Withdrawal was based on an internal adjudication using pooled placebo-controlled tegaserod data to identify potential cardiovascular ischemic signals. An independent committee conducted an external adjudication to evaluate 24 possible cardiovascular ischemic events (tegaserod: n = 20; placebo: n = 4) identified internally. A second independent

An Ex Vivo Study to Evaluate the Effect of Tegaserod on Platelet Activation and Aggregation. Tegaserod, an orally active, potent 5-hydroxytryptamine-4 serotonin receptor agonist, was previously indicated for irritable bowel syndrome but was voluntarily withdrawn due to potential cardiovascular side effects. In vitro studies suggested that tegaserod increased platelet aggregation , but these results were not reproduced or were inconclusive. We sought to assess ex vivo effects of tegaserod on platelet aggregation. In this double-blind, placebo-controlled, crossover study, we randomized a majority of healthy patients with no history of cardiovascular risk factors (n = 21) to receive tegaserod or matching placebo for 7 + 2 days followed by a 7- to 10-day washout period, and then patients were

Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials. Tegaserod was the first US Food and Drug Administration-approved drug for irritable bowel syndrome with constipation (IBS-C) in women and was recently reapproved for use. Recognizing that clinical trials were performed almost 20 years ago , we performed an integrated analysis on patient-reported outcomes relevant to current practice including previously unpublished data. Data from 4 12-week, randomized, placebo-controlled trials evaluating tegaserod 6 mg b.i.d. in patients with IBS-C were pooled. We analyzed 2 groups: all women (overall population) and women younger than 65 years without a history of cardiovascular ischemic events

Tegaserod An official website of the United States government Here's how you know Log inAccess keysNCBI HomepageMyNCBI HomepageMain ContentMain NavigationBookshelfSearch databaseBooksAll DatabasesAssemblyBiocollectionsBioProjectBioSampleBooksClinVarConserved DomainsdbGaPdbVarGeneGenomeGEO DataSetsGEO ProfilesGTRHomoloGeneIdentical Protein GroupsMedGenMeSHNLM LactationNo information is available on the clinical use of tegaserod during breastfeeding. Because of the potential for serious adverse reactions in the breastfed infant, an alternate drug is preferred.Drug LevelsMaternal Levels. Relevant published information was not found as of the revision date.Infant Levels. Relevant published information was not found as of the revision date.Effects in Breastfed

Effect of the 5-HT4 receptor agonist tegaserod on the expression of GRK2 and GRK6 in the rat gastrointestinal tract Tegaserod is a 5-hydroxytryptamine type 4 (5-HT) receptor agonist, formerly used in treating constipation predominant irritable bowel syndrome, which desensitizes 5-HT receptors in rat oesophagus and colon in vitro. Desensitization of 5-HT receptors is regulated by G-protein coupled receptor kinases. This study was designed to assess the effect of 5-HT receptor activation on the expression of GRK2 and GRK6 in the rat oesophagus and distal colon by acute administration of tegaserod. Rats were treated with a single dose of tegaserod (5 mg/kg) and tissue samples of the oesophagus and distal colon were prepared and level of GRK2 and GRK6 protein expression was determined using

|PrucalopridePrucalopride is a dihydro‐benzofuran‐carboxamidederivative and novel serotonin 5‐HT4 agonist that pro-motes GI motility. Given its highly selective affinity toonly 5‐HT4, the risk of target‐unrelated side effects likecardiac toxicity is theoretically minimized when com-pared to cisapride and tegaserod.100,101Prucalopridehas been shown to be well tolerated by toilet‐trainedpediatric patients with FC |TegaserodTegaserod is a serotonin 5‐HT4 agonist that promotesGI motility in patients with constipation that was with-drawn from the market in the United States due toserious adverse events.Recommendation 4.3.2:•We do not recommend the use of tegaserod inpediatric patients. (Agreement: 8/8).Question 5: What are the maintenance options forretrograde therapy in pediatric patients withrefractory constipation

is approved by the FDA for the treatment of occasional constipation and not CIC, it has been shown to be efficacious in individuals with CIC for up to 6 months (39). There are additional treatment trials comparing the efficacy of PEG with tegaserod, prucalopride, and lactulose, in which PEG demonstrated a similar or greater efficacy in individuals with CIC than these other medications (41,42), although

is approved by the FDA for the treatment of occasional constipation and not CIC, it has been shown to be efficacious in individuals with CIC for up to 6 months (39). There are additional treatment trials comparing the efficacy of PEG with tegaserod, prucalopride, and lactulose, in which PEG demonstrated a similar or greater efficacy in individuals with CIC than these other medications (41,42), although

on clinically relevant outcomes. The use of several other prokinetic agents has been proposed to hasten the resolution of ileus, including metoclopramide, naloxone, tegaserod, mitemcinal, ghrelin, prucalopride, and dexloxiglumide.[10] Few additional agents, which are not available in the United States, are considered to have a prokinetic effect: cisapride, levosulpiride, tegaserod, mosapride citrate, itopride

, cisapride, dopamine-antagonists (domperidone), propranolol, vasopressin, intravenouslidocaine and neostigmine was found either inconsistent or re-quired more evidence on clinically relevant outcomes. The useof several other prokinetic agents has been proposed to hastenthe resolution of ileus, including metoclopramide, naloxone,tegaserod, mitemcinal, ghrelin, prucalopride, and dexloxiglumide.10Few additional agents, which are not available in the United States,are considered to have a prokinetic effect: cisapride, levosulpiride,tegaserod, mosapride citrate, itopride hydrochloride, renzapride.However, their effectiveness is unclear.The goal of this review was to evaluate the existing evi-dence and create recommendations regarding the routine useof metoclopramide, erythromycin, and early enteral

: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethylene glycol laxatives, tricyclic antidepressants, selective serotonin reuptake inhibitors, and antispasmodics. The Guideline Panel reviewed the evidence and used the Evidence-to-Decision Framework to develop recommendations. The panel agreed on 9 recommendations for the management of patients with IBS-C. The panel made a strong recommendation for linaclotide (high certainty) and conditional recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), polyethylene glycol laxatives, tricyclic antidepressants, and antispasmodics (low certainty). The panel made a conditional recommendation against the use of selective serotonin reuptake inhibitors (low certainty).

]), or serotonergic agents (prucalopride and tegaserod) are generally preferred. Individuals experiencing concurrent abdominal pain and/or bloating may experience greater overall improvements from prescription therapies because these agents have been proven to reduce concurrent abdominal and bowel symptoms. Should initial prescription treatments fail, retrying past treatment options (if not adequately trialed

between abstracts and peer-reviewed publications.3,7 • One smaller RCT reported similar outcomes.8 Context: • Publication bias likely: Two open-label, 52 and 78-week safety studies with 1,557 and 1,743 patients completed in 2012 and 2013 not fully published9-11 but have been evaluated by the FDA.12 • At least two other IBS-C drugs have been withdrawn due to safety concerns: o Tegaserod: 5-HT4